menu search

CLLS / Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects
Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company recently entered into a collaboration agreement with AstraZeneca, receiving $245 million in cash and potential milestone payments for the development of up to 10 cell therapy candidates. Cellectis now has sufficient funds to run clinical trials for its candidates, including UCART20X22, UCART22, and UCART123, which are not part of the collaboration deal made with AstraZeneca. Read More
Posted: Nov 3 2023, 18:57
Author Name: Seeking Alpha
Views: 030154

CLLS News  

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

By Seeking Alpha
November 3, 2023

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin more_horizontal

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

By GlobeNewsWire
November 1, 2023

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology compa more_horizontal

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

By GlobeNewsWire
September 27, 2023

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com more_horizontal

Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 4, 2023

Cellectis SA (CLLS) Q2 2023 Earnings Call Transcript

Cellectis SA (NASDAQ:CLLS ) Q2 2023 Earnings Conference Call August 5, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andr more_horizontal

CLLS Stock: 23.01% Drop Explaination

By Pulse2
February 5, 2023

CLLS Stock: 23.01% Drop Explaination

The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why. more_horizontal

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

By GlobeNewsWire
December 1, 2022

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology co more_horizontal

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

By GlobeNewsWire
September 1, 2022

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology c more_horizontal

Why Cellectis' Shares Rose 22.7% This Week

By The Motley Fool
May 20, 2022

Why Cellectis' Shares Rose 22.7% This Week

The company bucked the recent downward trend for biotech companies. more_horizontal


Search within

Pages Search Results: